• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Accuracy of endoscopic ultrasound staging for T2N0 esophageal cancer: a National Cancer Database analysis.内镜超声对T2N0期食管癌分期的准确性:一项国家癌症数据库分析
J Gastrointest Oncol. 2018 Oct;9(5):887-893. doi: 10.21037/jgo.2018.01.16.
2
Endoscopic ultrasound for early stage esophageal adenocarcinoma: implications for staging and survival.内镜超声检查在早期食管腺癌中的应用:对分期和生存的影响。
Ann Thorac Surg. 2011 May;91(5):1509-15; discussion 1515-6. doi: 10.1016/j.athoracsur.2011.01.063. Epub 2011 Mar 24.
3
Comparative effectiveness of upfront esophagectomy versus induction chemoradiation in clinical stage T2N0 esophageal cancer: A decision analysis.临床 T2N0 期食管癌直接手术与诱导放化疗的疗效比较:决策分析。
J Thorac Cardiovasc Surg. 2018 May;155(5):2221-2230.e1. doi: 10.1016/j.jtcvs.2018.01.006. Epub 2018 Jan 12.
4
Induction therapy does not improve survival for clinical stage T2N0 esophageal cancer.诱导治疗并不能提高临床分期为T2N0的食管癌患者的生存率。
J Thorac Oncol. 2014 Aug;9(8):1195-201. doi: 10.1097/JTO.0000000000000228.
5
Predictors of Nodal Metastases for Clinical T2N0 Esophageal Adenocarcinoma.临床 T2N0 食管腺癌淋巴结转移的预测因素。
Ann Thorac Surg. 2018 Jul;106(1):172-177. doi: 10.1016/j.athoracsur.2018.02.087. Epub 2018 Apr 5.
6
Clinical T2N0 Esophageal Cancer: Identifying Pretreatment Characteristics Associated With Pathologic Upstaging and the Potential Role for Induction Therapy.临床T2N0期食管癌:识别与病理分期升级相关的治疗前特征及诱导治疗的潜在作用
Ann Thorac Surg. 2016 Jun;101(6):2102-11. doi: 10.1016/j.athoracsur.2016.01.033. Epub 2016 Apr 12.
7
Management of Clinical T2N0 Esophageal and Gastroesophageal Junction Adenocarcinoma: What Is the Optimal Treatment?临床 T2N0 食管及胃食管结合部腺癌的处理:最佳治疗方法是什么?
J Gastrointest Surg. 2022 Oct;26(10):2050-2060. doi: 10.1007/s11605-022-05441-7. Epub 2022 Aug 30.
8
Evaluation of the reliability of clinical staging of T2 N0 esophageal cancer: a review of the Society of Thoracic Surgeons database.评估 T2N0 期食管癌临床分期的可靠性:胸外科医师学会数据库的回顾性研究。
Ann Thorac Surg. 2013 Aug;96(2):382-90. doi: 10.1016/j.athoracsur.2013.03.093. Epub 2013 May 31.
9
Endoscopic ultrasound is inadequate to determine which T1/T2 esophageal tumors are candidates for endoluminal therapies.内镜超声不足以确定哪些 T1/T2 食管肿瘤适合腔内治疗。
J Thorac Cardiovasc Surg. 2014 Feb;147(2):765-71: Discussion 771-3. doi: 10.1016/j.jtcvs.2013.10.003. Epub 2013 Dec 4.
10
Predictors of pathologic upstaging in early esophageal adenocarcinoma: Results from the national cancer database.早期食管腺癌病理性升级的预测因素:来自国家癌症数据库的结果。
Am J Surg. 2018 Jul;216(1):124-130. doi: 10.1016/j.amjsurg.2017.07.015. Epub 2017 Jul 18.

引用本文的文献

1
Association of Guideline-Concordant Care with Superior Survival Outcomes for Clinical T2N0M0 Esophageal Squamous Cell Carcinoma.临床T2N0M0食管鳞状细胞癌的指南一致性治疗与更好的生存结果的关联
J Am Coll Surg. 2025 Sep 1;241(3):403-415. doi: 10.1097/XCS.0000000000001425. Epub 2025 Aug 14.
2
Clinical staging to differentiate T2 and T3 esophageal squamous cell carcinomas-essential details or just noise?区分T2和T3期食管鳞状细胞癌的临床分期——关键细节还是无关信息?
J Thorac Dis. 2024 Nov 30;16(11):7230-7232. doi: 10.21037/jtd-24-491. Epub 2024 Nov 29.
3
Association of survival with adjuvant radiotherapy for pN0 esophageal cancer.pN0期食管癌辅助放疗与生存的相关性
Aging (Albany NY). 2023 Apr 25;15(8):3158-3170. doi: 10.18632/aging.204677.
4
The ideal approach for treatment of cT1N+ and cT2Nany esophageal cancer.: a NCDB analysis.治疗 cT1N+ 和 cT2Nany 期食管癌的理想方法:NCDB 分析。
BMC Cancer. 2021 Dec 15;21(1):1334. doi: 10.1186/s12885-021-08896-0.
5
Clinical Predictors of Locally Advanced Pathology in Esophageal Adenocarcinoma.食管腺癌局部进展期病理的临床预测因素
Cureus. 2021 Oct 23;13(10):e18991. doi: 10.7759/cureus.18991. eCollection 2021 Oct.
6
Predicting lymph node metastases with endoscopic resection in cT2N0M0 oesophageal cancer: A systematic review and meta-analysis.cT2N0M0期食管癌内镜切除术后淋巴结转移的预测:一项系统评价和荟萃分析。
United European Gastroenterol J. 2020 Feb;8(1):35-43. doi: 10.1177/2050640619879007. Epub 2019 Sep 25.
7
Adjuvant radiotherapy for patients with pathologic node-negative esophageal carcinoma: A population based propensity matching analysis.辅助放疗用于病理淋巴结阴性食管癌患者:基于人群的倾向匹配分析。
Thorac Cancer. 2020 Feb;11(2):243-252. doi: 10.1111/1759-7714.13235. Epub 2019 Dec 11.
8
Management of clinical T2N0 esophageal cancer: a review.临床T2N0期食管癌的治疗:综述
J Thorac Dis. 2019 Aug;11(Suppl 12):S1629-S1632. doi: 10.21037/jtd.2019.07.85.
9
Prognostic value of tumor length and diameter for esophageal squamous cell cancer patients treated with definitive (chemo)radiotherapy: Potential indicators for nonsurgical T staging.根治性放化疗治疗食管鳞癌患者的肿瘤长度和直径的预后价值:非手术 T 分期的潜在指标。
Cancer Med. 2019 Oct;8(14):6326-6334. doi: 10.1002/cam4.2532. Epub 2019 Sep 4.
10
Upregulation of miR-17-92 cluster is associated with progression and lymph node metastasis in oesophageal adenocarcinoma.miR-17-92 簇的上调与食管腺癌的进展和淋巴结转移有关。
Sci Rep. 2019 Aug 20;9(1):12113. doi: 10.1038/s41598-019-48624-0.

本文引用的文献

1
Cancer Statistics, 2017.《2017 年癌症统计》
CA Cancer J Clin. 2017 Jan;67(1):7-30. doi: 10.3322/caac.21387. Epub 2017 Jan 5.
2
Clinical T2N0 Esophageal Cancer: Identifying Pretreatment Characteristics Associated With Pathologic Upstaging and the Potential Role for Induction Therapy.临床T2N0期食管癌:识别与病理分期升级相关的治疗前特征及诱导治疗的潜在作用
Ann Thorac Surg. 2016 Jun;101(6):2102-11. doi: 10.1016/j.athoracsur.2016.01.033. Epub 2016 Apr 12.
3
Role of neoadjuvant treatment in clinical T2N0M0 oesophageal cancer: results from a retrospective multi-center European study.新辅助治疗在临床T2N0M0期食管癌中的作用:一项欧洲多中心回顾性研究的结果
Eur J Cancer. 2016 Mar;56:59-68. doi: 10.1016/j.ejca.2015.11.024. Epub 2016 Jan 23.
4
Significant understaging is seen in clinically staged T2N0 esophageal cancer patients undergoing esophagectomy.在接受食管切除术的临床分期为T2N0的食管癌患者中,存在显著的分期不足情况。
Dis Esophagus. 2016 May;29(4):320-5. doi: 10.1111/dote.12334. Epub 2015 Feb 24.
5
Esophageal and esophagogastric junction cancers, version 1.2015.食管和胃食管交界处癌,第 1.2015 版。
J Natl Compr Canc Netw. 2015 Feb;13(2):194-227. doi: 10.6004/jnccn.2015.0028.
6
Induction therapy does not improve survival for clinical stage T2N0 esophageal cancer.诱导治疗并不能提高临床分期为T2N0的食管癌患者的生存率。
J Thorac Oncol. 2014 Aug;9(8):1195-201. doi: 10.1097/JTO.0000000000000228.
7
Treatment of clinical T2N0M0 esophageal cancer.临床T2N0M0期食管癌的治疗
Ann Surg Oncol. 2014 Nov;21(12):3739-43. doi: 10.1245/s10434-014-3929-6. Epub 2014 Jul 22.
8
Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901.手术与放化疗后手术治疗Ⅰ期和Ⅱ期食管癌的比较:FFCD 9901 期随机对照Ⅲ期试验的最终分析。
J Clin Oncol. 2014 Aug 10;32(23):2416-22. doi: 10.1200/JCO.2013.53.6532. Epub 2014 Jun 30.
9
Accuracy of endoscopic ultrasound in the diagnosis of T2N0 esophageal cancer.内镜超声在T2N0期食管癌诊断中的准确性
J Gastrointest Cancer. 2014 Sep;45(3):342-6. doi: 10.1007/s12029-014-9616-9.
10
Clinical stage T1-T2N0M0 oesophageal cancer: accuracy of clinical staging and predictive factors for lymph node metastasis.临床分期为T1-T2N0M0的食管癌:临床分期的准确性及淋巴结转移的预测因素
Eur J Cardiothorac Surg. 2014 Aug;46(2):274-9; discussion 279. doi: 10.1093/ejcts/ezt607. Epub 2014 Mar 14.

内镜超声对T2N0期食管癌分期的准确性:一项国家癌症数据库分析

Accuracy of endoscopic ultrasound staging for T2N0 esophageal cancer: a National Cancer Database analysis.

作者信息

Shridhar Ravi, Huston Jamie, Meredith Kenneth L

机构信息

Department of Radiation Oncology, Florida Hospital Orlando, Orlando, FL, USA.

Division of Surgical Oncology, Sarasota Memorial Hospital, Sarasota, FL, USA.

出版信息

J Gastrointest Oncol. 2018 Oct;9(5):887-893. doi: 10.21037/jgo.2018.01.16.

DOI:10.21037/jgo.2018.01.16
PMID:30505591
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6219972/
Abstract

BACKGROUND

To determine accuracy of clinical staging of T2N0 esophageal cancer from the National Cancer Database (NCDB).

METHODS

The NCDB was accessed to identify patients with T2N0M0 esophageal cancer (adenocarcinoma or squamous cell carcinoma) treated between 2004-2013 that underwent esophagectomy. Pathologic staging was compared to clinical stage. Univariate (UVA) and multivariate analysis (MVA) was performed to identify factors related to pathologic upstaging using Cox proportional hazard ratio.

RESULTS

We identified 1,840 patients with T2N0 esophageal cancer who underwent esophagectomy as first line therapy. The median age was 67 years. The vast majority of patients were male and had distal adenocarcinomas. Clinical staging in was accurate pathologically in 30.7% of patients. While there was a trend for worse accuracy with increasing year of diagnosis, there rate of pT0-2N0 was stable. Tumor length >3 cm was significantly associated with tumor upstaging, while poor differentiation was significantly associated with nodal upstaging. UVA and MVA identified younger age, tumor length >3 cm, and poor differentiation were significantly associated with overall upstaging. Gender, tumor location, and tumor histology were not prognostic.

CONCLUSIONS

Clinical staging for T2N0M0 esophageal cancer continues to remain highly inaccurate, however, rates of pT0-2N0 have steadily remained over 50%. Tumor length >3 cm and poor differentiation are strongly associated with pathologic upstaging.

摘要

背景

通过国家癌症数据库(NCDB)确定T2N0期食管癌临床分期的准确性。

方法

访问NCDB以识别2004年至2013年间接受食管切除术的T2N0M0期食管癌(腺癌或鳞状细胞癌)患者。将病理分期与临床分期进行比较。使用Cox比例风险比进行单因素(UVA)和多因素分析(MVA),以确定与病理分期上调相关的因素。

结果

我们识别出1840例接受食管切除术作为一线治疗的T2N0期食管癌患者。中位年龄为67岁。绝大多数患者为男性,患有远端腺癌。30.7%的患者临床分期在病理上是准确的。虽然随着诊断年份的增加,准确性有变差的趋势,但pT0 - 2N0的比例保持稳定。肿瘤长度>3 cm与肿瘤分期上调显著相关,而低分化与淋巴结分期上调显著相关。UVA和MVA确定年龄较小、肿瘤长度>3 cm和低分化与总体分期上调显著相关。性别、肿瘤位置和肿瘤组织学无预后意义。

结论

T2N0M0期食管癌的临床分期仍然极不准确,然而,pT0 - 2N0的比例一直稳定在50%以上。肿瘤长度>3 cm和低分化与病理分期上调密切相关。